Skip to main content

Table 5 One-way sensitivity analysis (per patient level)

From: Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany

Parameter

Variation

Cost / QALY

Incremental cost per QALY gained (€), Bedaquiline

BR alone

Linezolid plus BR

Delamanid plus BR

Bedaquiline plus BR

Versus BR alone

Versus Linezolid plus BR

Versus Delamanid plus BR

Base case

60,962 / 3.68

80,460 / 3.91

81,079 / 4.21

85,575 / 4.79

22,238

5787

7774

BR SCC rates at 6-months

+20% (37.2% SCC to 44.6%)

58,648 / 4.00

78,179 / 4.24

78,192 / 4.58

82,170 / 5.17

20,105

4316

6713

−20%(37.2% SCC to 29.7%)

63,037 / 3.36

82,518 / 3.56

83,807 / 3.82

89,010 / 4.35

26,384

8196

9802

Effect of bedaquiline on SCC rates

+20%

60,962 / 3.68

80,460 / 3.91

81,079 / 4.21

84,384 / 5.01

17,711

3569

4162

−20%

60,962 / 3.68

80,460 / 3.91

81,079 / 4.21

86,986 / 4.52

30,960

10,565

18,921

Maximum duration of linezolid treatment

42 to 24 weeks (duration of Bedaquiline treatment)

60,962 / 3.68

73,307 / 3.88

81,079 / 4.21

85,575 / 4.79

22,238

13,553

7774

Relapse after cure

+20%

61,232 / 3.65

80,732 / 3.87

81,421 / 4.16

85,716 / 4.77

21,809

5508

7092

−20%

60,684 / 3.72

80,180 / 3.95

80,729 / 4.26

85,433 / 4.81

22,701

6094

8552

Utility weight for no cure

plus20%

60,962 / 3.95

80,460 / 4.16

81,079 / 4.46

85,575 / 5.02

22,988

5983

8056

−20%

60,962 / 3.48

80,460 / 3.72

81,079 / 4.04

85,575 / 4.66

20,973

5465

7337

Utility for cure

Perfect health after cure

60,962 / 4.26

80,460 / 4.53

81,079 / 4.89

85,575 / 5.57

18,770

4905

6596

Discount rate

0% cost 3% outcomes

62,032 / 3.68

81,524 / 3.91

82,098 / 4.21

86,538 / 4.79

22,141

5672

7676

6% costs 3% outcomes

60,039 / 3.68

79,547 / 3.91

80,210 / 4.21

84,765 / 4.79

22,340

5903

7875

3% costs 0% outcomes

60,962 / 4.12

80,460 / 4.38

81,079 / 4.73

85,575 / 5.4

19,224

5015

6712

3% costs 6% outcomes

60,962 / 3.33

80,460 / 3.52

81,079 / 3.79

85,575 / 4.29

25,473

6611

8914

Cost for BR medication

+20%

66,824 / 3.68

86,271 / 3.91

86,831 / 4.21

91,177 / 4.79

22,003

5550

7514

−20%

55,099 / 3.68

74,649 / 3.91

75,327 / 4.21

79,974 / 4.79

22,474

6024

8034

Cost for AE’s

+20%

60,962 / 3.68

80,484 / 3.91

81,079 / 4.21

85,579 / 4.79

22,242

5764

7779

−20%

60,962 / 3.68

80,436 / 3.91

81,078 / 4.21

85,572 / 4.79

22,235

5811

7768

  1. AE Adverse event, BR Background regimen, QALY Quality-adjusted life-year, SCC Sputum culture conversion